-
|
Business Wire –
9:07 AM ET 01/12/2021
CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thorntons Global Health Care and Life Sciences Practices, has joined its Board of Directors and chair of the Audit Committee.
|
-
|
Reuters –
8:19 AM ET 01/11/2021
Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS HIGHLIGHTS RECENT PROGRESS AND EXPECTED TIMING OF 2021 MILESTONES, INCLUDING FOUR ONGOING AND PLANNED CLINICAL TRIALS. * Magenta Therapeutics Inc (MGTA) - ENDED 2020 WITH CASH RESERVES OF APPROXIMATELY $145 MILLION THAT ARE EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2023 Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
8:00 AM ET 01/11/2021
-- MGTA-145: Three Phase 2 clinical trials ongoing or planned to evaluate MGTA-145, a biologic used in combination with plerixafor to mobilize stem cells; the first clinical trial in patients with multiple myeloma; the first clinical trial with matched donors and patients with acute myeloid leukemia, acute lymphocytic lymphoma and myelodysplastic syndromes; and the first clinical trial in patie...
|
-
|
Business Wire –
8:00 AM ET 01/05/2021
Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 14th, 2021, at 10:50 a.m. ET, immediately followed by a Q&A session.
|
-
|
Reuters –
8:13 AM ET 12/07/2020
Magenta Therapeutics Inc (MGTA): * Magenta Therapeutics Inc (MGTA) - ANNOUNCES COMMENCEMENT OF FIRST PHASE 2 CLINICAL TRIAL OF MGTA-145 FOR STEM CELL MOBILIZATION. * MAGENTA - PLANS TO INITIATE PHASE 2 CLINICAL TRIAL IN EARLY 2021 USING MGTA-145 TO MOBILIZE, COLLECT STEM CELLS FOR TRANSPLANT IN PATIENTS WITH AML, ALL, MDS.
|
-
|
Business Wire –
8:00 AM ET 12/07/2020
Enrollment commenced in the MGTA-145 Phase 2 clinical trial of autologous transplant of multiple myeloma patients at Stanford University Oral presentation of Phase 1 clinical data presented at the 62nd American Society of Hematology Annual Meeting confirming MGTA-145 achieved proof-of concept: all safety and efficacy endpoints met and mobilized cells demonstrated functional superiority ov...
|
-
|
Reuters –
8:07 AM ET 12/04/2020
bluebird bio Inc: * MAGENTA THERAPEUTICS AND BLUEBIRD BIO ANNOUNCE A PHASE 2 CLINICAL TRIAL COLLABORATION TO EVALUATE MAGENTAS MGTA-145 FOR MOBILIZING AND COLLECTING STEM CELLS IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
8:00 AM ET 12/04/2020
Magenta Therapeutics (MGTA) and bluebird bio, Inc. today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. This press release features multimedia.
|
-
|
Reuters –
8:28 AM ET 11/09/2020
Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS APPOINTS STEVE MAHONEY AS CHIEF FINANCIAL AND OPERATING OFFICER Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
8:00 AM ET 11/09/2020
Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.
|
-
|
Reuters –
8:29 AM ET 11/05/2020
Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER FINANCIAL RESULTS. * Magenta Therapeutics Inc (MGTA) - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.37. * Magenta Therapeutics Inc (MGTA) - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2020, WERE $161.7 MILLION.
|
-
|
Business Wire –
8:00 AM ET 11/05/2020
Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Companys MGTA-117 conditioning program is on track to file an IND and generate clinical data in 2021; Magenta announced appointment of Lisa M. Olson, Ph.D., as Head of Research and Chief Scientific Officer Magenta named co-recipient of a U19 grant from the National Institut...
|
-
|
Business Wire –
11:02 AM ET 11/04/2020
Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and conditioning pipeline Oral presentation of completed Phase I clinical trial confirms that MGTA-145, a novel biologic, robustly mobilized large numbers of functional hematopoietic stem cells for autologous and allogeneic stem cell transplant ...
|
Page:
|
Today's and Upcoming Events
-
MGTA to announce Q4 earnings (Unconfirmed)
Past Events (last 90 days)
-
MGTA announced Q3 earnings.
Data provided by Thomson Reuters © 2021
|